WA
NVO

Walsh & Associates’s Novo Nordisk NVO Stock Holding History

Walsh & Associates’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-89
Closed -$3.27K – 276
2026
Q1 		$3.27K Buy
89
+7
+9% +$332 ﹤0.01% 206
2025
Q4 		$4.17K Buy
+82
New +$4.19K ﹤0.01% 205

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Walsh & Associates's NVO Position: Q2 2026 in Review

Walsh & Associates sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 89 shares — an estimated $3.27K sold.

Walsh & Associates first reported a position in NVO in Q4 2025 and held it in 2 quarters. The position peaked at $4.17K in Q4 2025. 1,346 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Walsh & Associates reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
  • Walsh & Associates sold 89 Novo Nordisk shares in Q2 2026, an estimated $3.27K.
  • Walsh & Associates first reported a position in Novo Nordisk in Q4 2025 and held it in 2 quarters.
  • Walsh & Associates's Novo Nordisk position peaked at $4.17K in Q4 2025.
  • 1,346 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Walsh & Associates's 13F filing for Q2 2026, filed 21 Jul 2026.